IL6 and breast carcinoma: In breast cancer, elevated serum interleukin‐6 (IL‐6) level is associated with a poor prognosis during eribulin treatment; however, the mechanisms underlying IL‐6‐mediated resistance and its potential as a therapeutic target remain unclear.